Chimeric Antigen Receptor News and Research

RSS

Unlocking the potential of RNA lipid nanoparticles to revolutionize cancer treatment

This paper discusses the use of RNA lipid nanoparticles for cancer immunotherapy, which has shown promising results in clinical use. However, only a small percentage of patients respond to existing immunotherapies, and the paper explores opportunities for improvement.

18 Apr 2023

Combination treatment could improve stem cell transplantation process for multiple myeloma patients

The standard treatment for patients with multiple myeloma often includes stem cell transplantation in which the patient's own stem cells are harvested and stored while the patient receives intensive chemotherapy to kill the cancer.

17 Apr 2023

CAR T-cell therapy improves quality of life for patients with blood cancers

Chimeric antigen receptor T-cell (CAR-T) therapy has transformed cancer treatment, yet relatively few studies have investigated the impact of the therapy on longitudinal patient quality of life – an aspect of care that often suffers from receiving traditional intensive cancer medications, such as chemotherapy.

30 Mar 2023

The breadth of immune responses following COVID-19 vaccination in hematology patients with diseases and treatments impacting B cell immunity

A study published in Cell Reports Medicine describes that COVID-19 vaccines induce strong T cell response in blood cancer patients, irrespective of antibody response and B cell numbers.

30 Mar 2023

Correcting abnormalities in solid tumor's blood vessels can improve efficacy of CAR-T cell therapy

A type of immune therapy called chimeric antigen receptor (CAR)-T cell therapy has revolutionized the treatment of multiple types of blood cancers but has shown limited efficacy against glioblastoma-;the deadliest type of primary brain cancer-;and other solid tumors.

14 Mar 2023

AI-assisted analysis helps find new targets for CAR-T cell therapy against acute myeloid leukemia

Unlike other forms of blood cancer, acute myeloid leukemia (AML) cannot currently be treated with CAR-T cell immunotherapy.

13 Mar 2023

Components of the gut microbiome could be used to better predict efficacy of CAR-T cell therapy

Even though, according to recent preliminary studies, the risk of dying from cancer has declined within the European Union in recent years, cancers remain among the leading causes of death.

13 Mar 2023

Fighting pancreatic cancer with gene and cell biotherapies

Pancreatic cancer is an incurable form of cancer, and gene therapies are currently in clinical testing to treat this deadly disease. A comprehensive review of the gene and cell biotherapies in development to combat pancreatic cancer is published in the peer-reviewed journal Human Gene Therapy.

6 Mar 2023

University of Vermont Cancer Center to offer a novel, highly effective form of cancer treatment

The University of Vermont Cancer Center will offer a novel, highly effective form of cancer treatment called CAR T-cell therapy beginning in February, when final accreditation and approval to begin treating patients is expected.

24 Feb 2023

Personalizing CAR-T cell stimulation during manufacturing can enhance its functionality

New adoptive T cell therapies -; in which T cells, the immune system's natural hunters patrolling the body for foreign adversaries, are retrieved from cancer-riddled patients, super-charged and amplified outside the body, and then infused back into the same patient -; are changing the prospects of cancer patients.

10 Feb 2023

New type of immunotherapy effective in mice with ovarian cancer

CAR T-cell therapy, a certain kind of cancer treatment in which the immune system's T cells are programmed to attack tumor cells, is effective in mice with ovarian cancer, according to a study published in The Journal for ImmunoTherapy of Cancer.

6 Feb 2023

Improving CAR-based-immunotherapies using a molecular anchor

Adding a molecular anchor to the key protein used to recognize cancer in cellular immunotherapies can make the treatments significantly more effective.

3 Feb 2023

CAR T cell therapy may enhance the effectiveness of surgery for solid tumors

CAR T cell therapy, an approach which reprograms patients' own immune cells to attack their blood cancers, may enhance the effectiveness of surgery for solid tumors, according to a preclinical study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

11 Jan 2023

Simple method increases the efficacy of T cell therapy by cytokine conjugation

The recent years have seen a wave of adoptive cell therapies (ACTs), a type of immunotherapy in which T cells (T cell transfer therapy) and other immune cells are obtained from patients, activated and multiplied outside the body, and infused in larger numbers back into the blood circulation to help fight cancers.

11 Jan 2023

Novel T cell receptor therapy shows early promise for treating solid tumors

Afamitresgene autoleucel (afami-cel; formerly ADP-A2M4), an adoptive T cell receptor (TCR) therapy targeting the MAGE-A4 cancer antigen, achieved clinically significant results for patients with multiple solid tumor types in a Phase I clinical trial led by researchers at The University of Texas MD Anderson Cancer Center.

9 Jan 2023

Researchers discover a highly potent biomarker for clinical response to CAR-T cell therapy

A MedUni Vienna research team has discovered a highly potent biomarker for clinical response to CAR-T cell therapy, describing the prerequisites for optimal use of this novel therapy for lymphoma treatment.

9 Jan 2023

Novel approach may prevent antibodies from triggering immune rejection of transplant cells

Researchers at UCSF have developed a novel, potentially life-saving approach that may prevent antibodies from triggering immune rejection of engineered therapeutic and transplant cells.

2 Jan 2023

Using synthetic gene circuits to better control the timing of immunotherapy

In two separate studies, researchers demonstrate how synthetic biology can be used to tackle a difficult issue in cancer immunotherapy: the way immunotherapy-related approaches focused on short-term killing of tumor cells may fail to eradicate tumors because growth of tumors happens on longer timescales.

16 Dec 2022

How human cell atlases provide the missing links between genes, diseases and therapies

A Nature Medicine journal perspective article describes the potential of cell atlases in shaping the future of medicine. Providing the missing link between genes and diseases, single-cell atlases make it possible to develop more precise and specific diagnostic tools by understanding the mechanisms of complex diseases.

12 Dec 2022

GOSH delivers world-first base-edited cell therapy for a patient with relapsed T cell leukemia

A patient with relapsed T cell leukemia has been given base-edited T-cells in a world-first use of a base-edited cell therapy, in a 'bench-to-bedside' collaboration between UCL and Great Ormond Street Hospital for Children (GOSH).